All In Biotech

Drug Trial Radar · NCT07807111

Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy

A Phase I/IIa Clinical Trial to Assess the Safety, Tolerability, and Efficacy of a Single Intravitreal Injection of SPVN20 Gene Therapy in Participants With Advanced Rod-Cone Dystrophy

Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

27

Planned (sponsor's estimate)

Start

Oct 8, 2025

Primary completion

Mar 2032

Study completion Mar 2032

Sponsor

Lead sponsor
SparingVisionIndustry
Sponsor type
Industry
First posted
Sep 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label, multi-center study is to evaluate the safety, tolerability, and efficacy of escalating doses of a gene therapy called SPVN20 administered via a single intravitreal injection in participants with advanced Rod-Cone Dystrophy.

Conditions

  • Retinitis Pigmentosa (RP)
  • Rod Cone Dystrophy

Interventions

  • SPVN20 (high dose)Biological

    SPVN20

  • SPVN20 (medium dose)Biological

    SPVN20

  • SPVN20 (low dose)Biological

    SPVN20

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: 6 months
  2. Ocular safetyTime frame: 6 months

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • Ghent University Hospital

    Ghent, Belgium · Recruiting

  • CHNO XV-XX Paris - CIC 1423

    Paris, France · Recruiting

  • Royal Victoria Eye And Ear Hospital

    Dublin, Ireland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.